Emerging Trends in Personalized Medicines

Emerging Trends in Personalized Medicines [3049-1347(e)] is a peer-reviewed online journal launched in 2024 that aims to unite all facets of personalized medicine under one platform. Case studies, well-liked articles, research papers, and reviews are all published by it. Molecular and translational sciences, systems biology pharmacogenomics/proteomics, omics association analysis, therapies and diagnostics, discussions of regulatory, social, ethical, and policy concerns, etc. are only a few of the scientific disciplines that are advanced by the publication of papers in the interdisciplinary journal personalized medicine. Researchers are expected to report their theoretical and empirical findings in as much detail as appropriate. As a result, there is no restriction on the paper’s length. To enable the replication of the findings, appropriate theoretical and simulation information must be available.

• • Personalized Cancer Treatment: Targeted therapeutics, small molecule–drug conjugates, receptor-mediated drug delivery, K-Ras and oncogenic signaling pathways, circulating tumor cells, tumor organoids, microfluidic tumor models, biomarker-guided oncology trials.
  • Pharmacogenomics and Pharmacogenetics: Single nucleotide polymorphisms, copy number variation, drug-metabolizing enzymes, genotype-guided dosing, pharmacokinetic variability, prediction of therapeutic response, pharmacogenomic clinical decision support, applications in anesthesiology and pain management.
  • Omics and Biomarkers: Genomics, transcriptomics, proteomics, metabolomics, and lipidomics, gene signatures, diagnostic, prognostic, and predictive biomarkers, quantitative proteomics and peptidomics, mass spectrometry, sample preparation, assay sensitivity and specificity, genetic testing.
  • Bioinformatics and Data Integration: Microarray and next-generation sequencing analysis, computational diagnostics, tumor classification, statistical and machine learning, multi-omics data integration, genome-wide association studies, biostatistics, medical informatics.
  • Drug Target Discovery and Personalized Therapy: Target identification and validation, drug–target interaction prediction, drug repositioning, pharmacotyping, nanomedicine for targeted delivery.
  • Antibody-Related Diseases: Antinuclear and antiphospholipid antibodies, autoimmune vasculopathy, mTOR pathway signaling, therapeutic proteins, antibody-conjugated payloads, anti-drug antibodies, immunogenicity testing, immunocapture assays.
  • Personalized Cell and Gene Therapy: Stem cells and cancer stem cell markers, regenerative medicine, gene transfer, gene therapy, growth factors in chronic wound healing, personalized vaccine development.
  • Neurological Personalized Medicine: Alzheimer’s and Parkinson’s disease, other neurodegenerative disorders, traumatic spinal cord injury, molecular profiling, targeted therapy, organ-on-chip models, deep brain stimulation, neuromodulation.
  • Nutrition, Exercise, and Lifestyle: Precision nutrition, gut microbiota, nutritional assessment and surveillance, dietary patterns, physical fitness, skeletal muscle metabolism, sleep and fatigue, mobile health technology.
  • Ethics, Regulation, and Policy: Governance, health care regulation, soft law and self-regulation, personal genomics, big data governance, disease taxonomies, public perceptions of personalized medicine, consumerization of health care.

  The journal publishes original research articles, reviews, case studies, and commentaries. Authors must provide the methods, data, and simulation details needed to replicate their findings. Studies that apply a uniform treatment with no stratification by patient genotype, biomarkers, or clinical profile are out of scope. The journal serves clinicians, clinical pharmacologists, geneticists, bioinformaticians, translational researchers, and bioethics and health policy specialists.